Open access
Aug 2026
Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies
In cetuximab–avelumab therapy, the absence of liver metastases and longer anti-EGFR-free interval might represent potential biomarkers and single-agent cetuximab activity is not influenced by clinical factors.
D. Ciardiello, G. Martini, F. Pietrantonio et al.
· ESMO gastrointestinal oncolo... · 0 citations